

Giorgia Teresa Maniscalco

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2720358/publications.pdf>

Version: 2024-02-01

28
papers

1,175
citations

623734

14
h-index

501196

28
g-index

28
all docs

28
docs citations

28
times ranked

2071
citing authors

#	ARTICLE	IF	CITATIONS
1	Switch from sequestering to anti-CD20 depleting treatment: disease activity outcomes during wash-out and in the first 6 months of ocrelizumab therapy. <i>Multiple Sclerosis Journal</i> , 2022, 28, 93-101.	3.0	13
2	Interferon Beta-1a treatment promotes SARS-CoV-2 mRNA vaccine response in multiple sclerosis subjects. <i>Multiple Sclerosis and Related Disorders</i> , 2022, 58, 103455.	2.0	13
3	Flu vaccination in multiple sclerosis patients: a monocentric prospective vaccine-vigilance study. <i>Expert Opinion on Drug Safety</i> , 2022, 21, 979-984.	2.4	4
4	Long term persistence of SARS-CoV-2 humoral response in multiple sclerosis subjects. <i>Multiple Sclerosis and Related Disorders</i> , 2022, 62, 103800.	2.0	4
5	Transition to secondary progression in relapsing-onset multiple sclerosis: Definitions and risk factors. <i>Multiple Sclerosis Journal</i> , 2021, 27, 430-438.	3.0	19
6	Anti-MOG-associated demyelinating disorders: two sides of the same coin. <i>Neurological Sciences</i> , 2021, 42, 1531-1534.	1.9	9
7	Disease-Modifying Therapies and Coronavirus Disease 2019 Severity in Multiple Sclerosis. <i>Annals of Neurology</i> , 2021, 89, 780-789.	5.3	370
8	Late-onset neutropenia (LON) recur in a MS patient after the second cycle of ocrelizumab: a case report. <i>Neurological Sciences</i> , 2021, 42, 3933-3935.	1.9	6
9	Influenza Vaccine Hesitancy in Patients with Multiple Sclerosis: A Monocentric Observational Study. <i>Brain Sciences</i> , 2021, 11, 890.	2.3	13
10	DMTs and Covid-19 severity in MS: a pooled analysis from Italy and France. <i>Annals of Clinical and Translational Neurology</i> , 2021, 8, 1738-1744.	3.7	86
11	Severe Multiple Sclerosis Relapse After COVID-19 Vaccination: A Case Report. <i>Frontiers in Neurology</i> , 2021, 12, 721502.	2.4	37
12	Autoimmune encephalitis: A retrospective monocentric experience. <i>Multiple Sclerosis and Related Disorders</i> , 2021, 55, 103191.	2.0	1
13	Treatment of multiple sclerosis with rituximab: A multicentric Italian-Swiss experience. <i>Multiple Sclerosis Journal</i> , 2020, 26, 1519-1531.	3.0	38
14	Characteristics and treatment of Multiple Sclerosis-related trigeminal neuralgia: An Italian multi-centre study. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 37, 101461.	2.0	14
15	Epileptic seizures of suspected autoimmune origin: a multicentre retrospective study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2020, 91, 1145-1153.	1.9	19
16	Preliminary Results of the FASM Study, an On-Going Italian Active Pharmacovigilance Project. <i>Pharmaceuticals</i> , 2020, 13, 466.	3.8	5
17	Remission of early persistent cladribine-induced neutropenia after filgrastim therapy in a patient with Relapsing - Remitting Multiple Sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 43, 102151.	2.0	13
18	First therapy choice in newly diagnosed Multiple Sclerosis patients: A multicenter Italian study. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 42, 102059.	2.0	4

#	ARTICLE	IF	CITATIONS
19	GABA _A receptor autoimmunity after alemtuzumab treatment for multiple sclerosis. <i>Neurology</i> , 2020, 95, 399-401.	1.1	11
20	Effects of THC/CBD oromucosal spray on spasticity-related symptoms in people with multiple sclerosis: results from a retrospective multicenter study. <i>Neurological Sciences</i> , 2020, 41, 2905-2913.	1.9	12
21	Determinants of therapy switch in multiple sclerosis treatment-naïve patients: A real-life study. <i>Multiple Sclerosis Journal</i> , 2019, 25, 1263-1272.	3.0	36
22	Reduced Annexin A1 Expression Associates with Disease Severity and Inflammation in Multiple Sclerosis Patients. <i>Journal of Immunology</i> , 2019, 203, 1753-1765.	0.8	24
23	Outcomes after fingolimod to alemtuzumab treatment shift in relapsing/remitting MS patients: a multicentre cohort study. <i>Journal of Neurology</i> , 2019, 266, 2440-2446.	3.6	16
24	A multicentre observational analysis of Persistence to Treatment in the new multiple sclerosis era: the RESPECT study. <i>Journal of Neurology</i> , 2018, 265, 1174-1183.	3.6	23
25	THC/CBD oromucosal spray in patients with multiple sclerosis overactive bladder: a pilot prospective study. <i>Neurological Sciences</i> , 2018, 39, 97-102.	1.9	19
26	Early neutropenia with thrombocytopenia following alemtuzumab treatment for multiple sclerosis: case report and review of literature. <i>Clinical Neurology and Neurosurgery</i> , 2018, 175, 134-136.	1.4	20
27	Assessing association of comorbidities with treatment choice and persistence in MS. <i>Neurology</i> , 2017, 89, 2222-2229.	1.1	50
28	Glycolysis controls the induction of human regulatory T cells by modulating the expression of FOXP3 exon 2 splicing variants. <i>Nature Immunology</i> , 2015, 16, 1174-1184.	14.5	296